Alamar Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
ALMR$31.50-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(21,325) | $(7,659) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 1,167 | 888 |
| Stock-based compensation | 1,467 | 619 |
| Accretion and amortization of premiums and discounts on investments, net | — | (208) |
| Loss on remeasurement of convertible notes | 8,594 | — |
| Convertible note issuance costs included in net income | 361 | — |
| Unrealized foreign exchange loss (gain) | 165 | (134) |
| Non-cash operating lease costs | 461 | 465 |
| Amortization of debt issuance costs | 67 | 42 |
| Change in fair value of warrant liabilities | 84 | (19) |
| Changes in assets and liabilities: | ||
| Accounts receivable | (6,854) | (533) |
| Inventory | (1,265) | (2,357) |
| Contract assets | — | 282 |
| Net investment in sales-type lease | — | 86 |
| Prepaid expenses and other current assets | (1,960) | 191 |
| Other noncurrent assets | (327) | 182 |
| Accounts payable | 1,339 | 578 |
| Operating lease liabilities | (1,087) | (463) |
| Accrued expenses and other liabilities | (1,234) | (5,028) |
| Net cash used in operating activities | (20,347) | (13,068) |
| Cash flows from investing activities: | ||
| Maturities of short-term investments | — | 18,000 |
| Purchases of property and equipment | (600) | (554) |
| Capitalized software development costs | (178) | (428) |
| Net cash (used in) provided by investing activities | (778) | 17,018 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of convertible notes | 56,500 | — |
| Payment of third-party debt issuance costs | (324) | — |
| Proceeds from issuance of common stock upon exercise of stock options | 1,803 | 243 |
| Payment of deferred offering costs | (2,218) | — |
| Net cash provided by financing activities | 55,761 | 243 |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | (52) | 133 |
| Net increase in cash, cash equivalents and restricted cash | 34,584 | 4,326 |
| Cash, cash equivalents and restricted cash at beginning of period | 34,909 | 31,677 |
| Cash, cash equivalents and restricted cash at end of period | $69,493 | $36,003 |
| Supplemental disclosure of cash-flow information: | ||
| Cash paid for interest | $156 | $3 |
| Noncash investing and financing items: | ||
| Vesting of early exercised stock options | 102 | 7 |
| Equipment transferred to inventory | 214 | 169 |
| Deferred offering costs included in accrued liabilities | 2,090 | — |
| Property and equipment included in accounts payable and accrued liabilities | 583 | 457 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.